Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801678 · ClinicalTrials.gov registry record
Refractive Outcomes Utilizing Two SS-OCT Biometers for IOL Power Calculations
A clinical trial of Cataract, sponsored by The Eye institute of Utah.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06801678: Recruiting study of Cataract, sponsored by The Eye institute of Utah.
NCT06801678 is a study of Cataract that is actively recruiting participants, run by The Eye institute of Utah. The registered enrollment target is 50 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801678, a study of Cataract, is actively recruiting participants, sponsored by The Eye institute of Utah.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate and compare the potential refractive outcomes using the Argos 1.5 biometer in the surgical planning for cataract extraction to that obtained from IOLMaster 700. Both devices are used as standard of care in surgical planning optimization for patients undergoing cataract surgery.
Primary Outcome
Predicted refraction is defined as the refractive power predicted by the IOL calculation formula. The predicted refraction for planned IOL power when using Argos 1.5 will be compared to IOL Master 700 for available formulae common to both devices (e.g. SRK/T, Barrett Universal II, Holladay I, Holladay II etc.) using forest plots. Data for Barrett TAL \[Argos only\] will be analysed using descriptive statistics
Conditions Studied
Study Locations (1)
Utah
- The Eye Institute of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01-09 |
| Est. Completion | 2025-02-22 |
What NCT06801678 shows while recruiting
NCT06801678 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 0 interventions.
NCT06801678 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06801678 about?
NCT06801678 is a clinical study titled "Refractive Outcomes Utilizing Two SS-OCT Biometers for IOL Power Calculations". The purpose of this study is to evaluate and compare the potential refractive outcomes using the Argos 1.5 biometer in the surgical planning for cataract extraction to that obtained from IOLMaster 700. Both devices are used as standard of care in surgical planning optimization for patients undergoin...
What is the current status of trial NCT06801678?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-01-09. Estimated completion is 2025-02-22.
What conditions does trial NCT06801678 study?
This clinical trial studies the following conditions: Cataract.
Who is sponsoring clinical trial NCT06801678?
This trial is sponsored by The Eye institute of Utah, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06801678 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06801678's enrollment target sits among peer trials
50 57th of 83 higher than 25 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI